301047.SHE Sino BiologicalInc.
- Market cap
- CNY 14.3B
- P/E
- 79.9x
- P/B
- 2.77x
- ROE
- 3.7%
- Dividend yield
- 4.26%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301047.SHE undervalued?
Graham numberThe Graham number of Sino BiologicalInc. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sino BiologicalInc. fundamental analysis
No fundamental analysis for Sino BiologicalInc. yet.
Sino BiologicalInc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sino BiologicalInc.
Sino Biological,Inc. engages in the provision of recombinant protein and antibody reagents for life science researchers in China and internationally. The company offers recombinant proteins, antibodies, cDNA clones, kits, serum-free media, protein modification, qPCR primers, cell lysates, and purification reagents. It also provides comprehensive solutions, including autoimmune disease research, kinase drug discovery, cytokine and growth factor, SARS-CoV-2 variants research, …
Full company profileSino BiologicalInc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sino BiologicalInc. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 181M | 1.60B | 965M | 575M | 646M | 614M | 700M | 805M |
| Gross Profit | 152M | 1.55B | 907M | 489M | 530M | 450M | 513M | 601M |
| Operating Income | 40.3M | 1.36B | 779M | 228M | 164M | 54.7M | 104M | 173M |
| EBITDA | 84.0M | 1.37B | 874M | 383M | 362M | 236M | 274M | 216M |
| Net Income | 36.4M | 1.13B | 720M | 303M | 260M | 122M | 148M | 189M |
| EPS | 0.38 | 12 | 5.57 | 2.34 | 2.01 | 1.00 | 1.21 | 1.55 |
| Balance Sheet | ||||||||
| Total Assets | 187M | 1.49B | 6.89B | 6.58B | 6.60B | 6.05B | 5.54B | 5.40B |
| Total Liabilities | 37.3M | 190M | 138M | 211M | 234M | 282M | 228M | 230M |
| Shareholders' Equity | 150M | 1.30B | 6.75B | 6.37B | 6.37B | 5.77B | 5.31B | 5.17B |
| Cash & Short-term Investments | 10.3M | 56.1M | 2.87B | 2.38B | 1.32B | 233M | 322M | 202M |
| Cash Flow | ||||||||
| Operating Cash Flow | 41.8M | 1.09B | 643M | 249M | 323M | 114M | 146M | - |
| Capital Expenditure | 33.6M | 18.3M | 47.9M | 156M | 1.04B | 69.9M | 101M | 149M |
| Free Cash Flow | 8.15M | 1.07B | 595M | 93.3M | -721M | 43.8M | 45.1M | 52.6M |
| Ratios | ||||||||
| ROE | 24.3% | 86.8% | 10.7% | 4.8% | 4.1% | 2.1% | 2.8% | 3.7% |
| ROA | 19.5% | 75.8% | 10.4% | 4.6% | 3.9% | 2.0% | 2.7% | 3.5% |
| Net Profit Margin | 20.1% | 70.6% | 74.6% | 52.7% | 40.2% | 19.9% | 21.1% | 23.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sino BiologicalInc. dividends
- Dividend yield
- 4.26%
- Forward dividend
- 2.20 CNY
- Payout ratio
- 411.7%
- Ex-dividend date
- Sep 21, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 608M | 5.00 | 411.7% |
| 2024 | CNY 256M | 2.10 | 209.6% |
| 2023 | CNY 258M | 2.00 | 99.3% |
| 2022 | CNY 680M | 5.26 | 224.5% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | CNY 20.8K | 0.00 | 0.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.9:1 on Mar 30, 2022.
Who owns Sino BiologicalInc.
- Insiders 63.08%
- Institutions 0.68%
- Public & others 36.24%
- Shares outstanding 122M
- Free float 43.3M
Sino BiologicalInc. company profile
- Company name
- Sino BiologicalInc.
- Ticker
- 301047.SHE
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,069
- Fiscal year end
- December
- Address
- Building 11, Beijing, China, 100176
- Phone
- 86 40 0890 9989
- Website
- sinobiological.com
About Sino BiologicalInc.
Sino Biological,Inc. engages in the provision of recombinant protein and antibody reagents for life science researchers in China and internationally. The company offers recombinant proteins, antibodies, cDNA clones, kits, serum-free media, protein modification, qPCR primers, cell lysates, and purification reagents. It also provides comprehensive solutions, including autoimmune disease research, kinase drug discovery, cytokine and growth factor, SARS-CoV-2 variants research, comprehensive CAR-T therapy, 3D organoids research, ADC development, influenza vaccine development, and multispecific antibody development solutions, as well as solutions for MSCs therapy and in vitro efficacy evaluation. It serves academic research institutions, biotech companies, and pharmaceutical companies. Sino Biological,Inc. was founded in 2016 and is headquartered in Beijing, China.
Sino BiologicalInc. management
5- Dr. Liangzhi Xie Ph.D.Founder & Chairman · born 1966
- Mr. Zhang Jie Ph.D.GM, Director of R&D and Director · born 1973
- Mr. Tao FengCFO, Secretary to the Board & Non-Independent Director · born 1981
- Mr. Zhou YongProduction Director · born 1982
- Xiaoming MaAccounting Supervisor & Head of Accounting Department